Heidi Lopez De Diego

This inventor holds 33 USPTO granted patents and 11 published patent applications, plus 9 CIPO patents and 15 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: H. Lundbeck A/s, Cephalon, Inc., Bioei Therapies Corp. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heidi Lopez De Diego. Retrieved from https://idiyas.com/inventor/heidi-lopez-de-diego

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 11)

% Patents Active = 72.7

CIPO Patents = 9 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 11)

Average Co-Inventor Count = 3.2

ph-index = 7

Forward Citations = 133(Granted Patents)

Location History:

Kokkedal, DK (2005)
Naerum, DK (2010 - 2018)
Nærum, DK (2010 - 2022)
Valby, DK (2021 - 2024)

Company Filing History:

4. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Areas of Expertise:

Crystalline Forms

Liquid Formulations

MAGL Inhibitor

Nalmefene Salts

Serotonin Reuptake

Cognitive Impairment

Alzheimer's Disease

Hydrochloride Dihydrate

Pharmaceutical Compounds

Piperazine Compounds

Dimethylphenylsulfanyl

Trimethylpiperazine

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421271 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR, 10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-09-23),

2. 12152029 - Crystalline forms of a MAGL inhibitor (2024-11-26),

3. 11858954 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2024-01-02),

4. 11458134 - 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment (2022-10-04),

5. 11279682 - Vortioxetine pyroglutamate (2022-03-22),

6. 11130775 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2021-09-28),

7. 10857149 - Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine (2020-12-08),

8. 10287261 - Vortioxetine pyroglutamate (2019-05-14),

9. 10071963 - Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's disease (2018-09-11),

10. 10034876 - Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine (2018-07-31),

11. 9938286 - Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption (2018-04-10),

12. 9861630 - [object Object] (2018-01-09),

13. 9725458 - Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption (2017-08-08),

14. 9475748 - Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (2016-10-25),

15. 9315459 - Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine (2016-04-19),

Title: Heidi Lopez de Diego: Pioneering Inventor in Neurodegenerative Disease Treatments

Introduction:

Heidi Lopez de Diego, a prolific inventor based in Naerum, DK, has made significant contributions to the field of pharmaceuticals with a focus on neurodegenerative diseases. With an impressive portfolio of 25 patents to her name, Heidi's innovative work has the potential to transform the landscape of treatment for conditions like Parkinson's Disease.

Latest Patents:

Heidi's latest patents showcase her commitment to developing groundbreaking therapies. One of her notable inventions includes solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid, a prodrug of a catecholamine for treating neurodegenerative diseases. Additionally, the compound 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine demonstrates promising activity for cognitive impairment treatment.

Career Highlights:

Heidi Lopez de Diego has stamped her authority in leading pharmaceutical companies, including H. Lundbeck A/S and Bioei Therapies Corp. Her expertise and visionary approach have been instrumental in spearheading innovative drug development initiatives, particularly in the realm of neuroscience.

Collaborations:

Throughout her career, Heidi has collaborated with esteemed professionals in the field. Notable coworkers such as Benny Bang-Andersen and Rene Holm have contributed to the success of her projects, fostering a culture of innovation and excellence.

Conclusion:

Heidi Lopez de Diego's exceptional patent portfolio and groundbreaking research underscore her position as a trailblazer in pharmaceutical innovation. Her unwavering dedication to advancing treatments for neurodegenerative diseases serves as an inspiration to aspiring inventors and exemplifies the transformative power of innovation in healthcare.

Profile summary based on public USPTO records.